competent GL261 glioma model which recapitulates human disease and host immune barriers. We generated a library of B7-H3 CARs with different transmembrane (CD8, CD28), costimulatory (CD28, 4-1BB), and activation (ζ, mutζ) domains. We then compared their cytolytic activity, expansion, and anti-tumor activity. Results show that B7-H3 CARs with CD28 transmembrane and costimulatory domains have superior efficacy compared to CARs with CD8 and 4-1BB domains. Additionally, CARs with mutated ζ activation domain have better overall persistence. However, providing costimulation signals through CD28 or 4-1BB alone does not induce superior anti-glioma efficacy of B7-H3 CAR T-cells *in vivo*. Thus, we next investigated whether incorporating 4-1BB signaling into CD28-based CARs using *in tran*s design enhances the therapeutic efficacy of B7-H3 CAR T-cells. We found that in repeat stimulation assays, surface expression of 4-1BBL enhanced expansion of B7H3 CAR T-cells at least 300-folds more than T-cells with CD28 or 4-1BB costimulatory domains alone. Additionally, 4-1BBL expression significantly enhanced the sequential killing capacity compared to CD28- or 41BB-based B7-H3 CAR T-cells. High dimensional flow cytometry analysis of GL261 tumors post CAR T-cell injection revealed unique immune clusters including dendritic cells and lymphoid predominant populations in mice treated with 4-1BBL expressing CARs. Thus, expression of 4-1BBL on CD28-based CARs reshaped the TME and enhanced persistence and anti-glioma efficacy of B7-H3 CAR T-cells. Studies examining transcriptional and epigenetic programs, and TME/CAR T-cell interactions are in progress. Results will define pathways that dictate CAR T-cell performance and will identify unique mechanisms for further improvements utilizing other members of TNF-superfamily.

IMMU-02. TARGETED INNOVATIVE ANTIBODY FRAGMENT-BASED IMMUNOTHERAPY FOR MEDULLOBLASTOMA

Judith Niesen[1,2], Christina Krüger[3], Naomé Kreuter[4], Undine Haferkamp[5], Ole Pless[5], Ulrich Schüller[6,7]; [1]Mildred Scheel Cancer Career Centre HaTriCS[4], University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. [2]Department of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, (Research Institute Children's Cancer Centre Hamburg), Hamburg, Germany. [3]Research Institute Children's Cancer Centre Hamburg,, Hamburg, Germany. [4]Research Institute Children's Cancer Centre Hamburg, Hamburg, Germany. [5]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP,, Hamburg, Germany. [6]Department of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf (Research Institute Children's Cancer Centre Hamburg), Hamburg, Germany. [7]Institute of Neuropathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Medulloblastoma (MB) is the most common malignant pediatric brain tumor accounting for ~20 % of childhood brain tumors. One third of all MB are characterized by constitutive activation of the Sonic Hedgehog (SHH)-signaling pathway. This tumor type shows overexpression of the epidermal growth-factor receptor (EGFR), which we detected in SHH-MB patient samples, transgenic SHH MB mouse models, and MB-cell lines. In contrast, non-neoplastic cells only express EGFR at low levels. Intensive radio-/chemotherapy often leaves the young patients with significant long-term burdens including problems in brain development and cognitive deficits. Thus, there is an urgent need to develop new targeted therapies that can prevent tumor recurrence without affecting healthy cells. We selected EGFR as a potential therapy target using EGFR-specific antibody fragments (scFvs) as part of immunoconjugates, namely bispecific T-cell engagers (BiTEs) and immunotoxins (ITs). Both, the EGFR-specific BiTEs and the ITs showed specific binding and cytotoxic activity in MB cells. Effector- and target-cell specificity was demonstrated via flow cytometry for the BiTEs. BiTEs and ITs selectively killed MB-tumor cells and showed pro-apoptotic effects without unspecific effects. Furthermore, preliminary results from an innovative hiPSC-based in vitro-BBB-model suggest, that the ITs are able to cross the BBB. Finally, by having a functional cloning- and expression system for the BiTEs and ITs available, target-scFvs can be easily exchanged by novel antigens or peptides to obtain additional targeted immunotherapies. Together, these results pave the way for preclinical in vivo experiments and future clinical trials in patients with SHH MB.

IMMU-03. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OVERALL SURVIVAL OF IDH1 WILD-TYPE MGMT PROMOTER-UNMETHYLATED GBM PATIENTS

Stefaan Van Gool, Jennifer Makalowski, Michael Bitar, Peter Van de Vliet, Volker Schirrmacher, Wilfried Stuecker; IOZK, Köln, Germany

The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months.

We retrospectively analysed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015-06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47y (range 18-69) and a KPI of 70 (50-100). Extent of resection was complete (11), <complete (12) or not documented (9). Seven patients were treated with surgery/radio(chemo)therapy and subsequent IMI (Group-1); 25 patients were treated with radiochemotheraphy followed by maintenance TMZ plus IMI during and after TMZ (Group-2). Age, KPI and extent of resection were not different amongst both groups. The median OS of group-1 patients was 11m (2y OS: 0%). Surprisingly the median OS of group-2 patients was 22m with 2y OS of 36% (CI95%: 16-57), which was significantly (Log-rank: p = 0.0001) different from group-1. The data suggest that addition of IMI after local therapy on its own has no relevant effect on OS in these GBM patients, similar to maintenance TMZ. However, the combination of both TMZ + IMI significantly improved OS. This finding might also have implications in the search for novel combined treatment approaches for children with malignant glioma.

IMMU-04. TRANSCRIPTIONAL ANALYSIS REVEALS DISTINCT MICROENVIRONMENTAL SUBGROUPS ACROSS PEDIATRIC NERVOUS SYSTEM TUMORS

Arash Nabbi[1], Pengbo Beck[2], Alberto Delaidelli[3], Derek A. Oldridge[4,5], Sumedha Sudhaman[6], Kelsey Zhu[1], S.Y. Cindy Yang[1], David T. Mulder[1], Jeffrey P. Bruce[1], Joseph N. Paulson[7], Pichai Raman[8], Yuankun Zhu[8], Martin Sill[2], Sebastian Brabetz[2], Sander Lambo[2], Pascal D. Johann[2], Adam C. Resnick[8], Poul H. Sorensen[3], David Malkin[6], Marcel Kool[2,9], David T.W. Jones[2], Stefan M. Pfister[2], Natalie Jäger[2], Trevor J. Pugh[1]; [1]Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [2]Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany. [3]Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. [4]Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. [5]Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. [6]The Hospital for Sick Children, Toronto, ON, Canada. [7]Department of Biostatistics, Genentech Inc, San Francisco, CA, USA. [8]Department of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. [9]Máxima Center for pediatric oncology, Utrecht, Netherlands

INTRODUCTION: Recent clinical trials of immune checkpoint inhibitors indicated 5-11% response rate in pediatric patients depending on cancer type and expression of target proteins. Currently, a systematic analysis characterizing the immune microenvironment of childhood tumors is lacking. The main objective of this study is to uncover the features of immune microenvironment in pediatric nervous system tumors (pedNST). METHODS: We compiled transcriptomes of 925 tumors from three initiatives, Therapeutically Applicable Research To Generate Effective Treatments (TARGET, n = 149), International Cancer Genome Consortium (ICGC, n = 195) and Children Brain Tumor Tissue Network (CBTN, n = 581). We analyzed the performance of immune deconvolution tools and used publicly available datasets to define immune genesets. We conducted a consensus analysis to assign genes to cell-types and identify immunological groups. RESULTS: We found wide variability in immune infiltration across and within cancer types ranging from cold tumors such as medulloblastoma (2.7% infiltrate) to infiltrated entities such as neurofibroma (22.6%). Consensus clustering revealed four distinct immune clusters. The pediatric inflamed group (10%) included MYCN non-amplified neuroblastoma and ATRT. The myeloid-predominant group (30%) showed decreased infiltration of lymphoid cells but enrichment of myeloid cell genesets. The pediatric-cold group (42%) harbored no enrichment of immune genesets and included 72% of ependymomas and 65% of medulloblastomas. The immune excluded group (18%) showed depletion of immune cell-types and included sonic-hedgehog medulloblastoma. 71% of pedNST belonged to the lymphocyte depleted or immunologically quiet clusters, indicating the cold immune microenvironment in pedNST compared to adult cancers. CONCLUSION: We report characteristics of the immune microenvironment in pedNST. We found an overall cold microenvironment with low lymphocyte infiltration in this population compared to common adult cancers. We identified ~10% of tumors harboring a relatively inflamed microenvironment. Our data uncover characteristics of immune infiltration in pediatric tumors with potential implications to guide therapy.

IMMU-05. INTEGRATIVE TRANSCRIPTOMIC ANALYSIS OF PILOCYTIC ASTROCYTOMAS REVEALS CNS REGION-ASSOCIATED CHARACTERISTICS

Jacob S. Rozowsky[1], Mariëtte E.G. Kranendonk[1], Antoinette Y.N. Schouten-van Meeteren[1], Lisethe Meijer[1], Eelco W. Hoving[1], Friso G. Calkoen[1], Pieter Wesseling[1,2], Lennart A. Kester[1], Jasper van der Lugt[1]; [1]Princess Máxima Center for

Pediatric Oncology, Utrecht, Netherlands. [2]Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, Netherlands

BACKGROUND: Recent insights highlight how the initiation and growth of gliomas is governed by interactions between glioma stem-like cells and stromal and immune cells in the tumor microenvironment. For pilocytic astrocytomas, the most common pediatric CNS tumor, this relationship is so far less explored. To this end, we used transcriptomic methods to investigate inter-patient heterogeneity, and the stromal and immune microenvironment of pilocytic astrocytomas. MATERIALS AND METHODS: In this study, we collected clinical data and tissue of 90 pre-treatment pilocytic astrocytomas from different CNS compartments: posterior fossa (n=57), supratentorial (n=23), and spinal (n=10). The median age at primary resection was 8 (0-16) years, and 66% (n=59) of our cohort was male. From 10 of these patients, we collected post-treatment samples after re-growth of the tumor as well. We characterized all samples by bulk RNA-sequencing and DNA methylation profiling, and selected a subset (n=10) samples for single-nucleus RNA-sequencing. RESULTS: Principal component analysis and unsupervised clustering of bulk sequencing data revealed gene expression patterns correlating to the CNS location of the tumor, consistent with prior reports. Using differential expression and functional pathway analysis, we found CNS region-associated enrichment of cell-cycle, developmental, and inflammatory-related pathways. With respect to the glioma immune microenvironment, supratentorial tumors were enriched in gene-sets related to T-cell activation and cytotoxicity, while spinal tumors had lowest expression of immune-related genes. Moreover, spinal tumors were enriched in pathways related to cell division, nucleotide synthesis, and neurodevelopment. To resolve cell-type expression programs of glioma and immune cells in the microenvironment, we collected and analyzed snRNA-seq data of 10 pilocytic astrocytomas, as well as harmonized our findings with a pre-existing dataset from Vladoiu, 2019. CONCLUSION: Our integrative transcriptomic analysis of pilocytic astrocytomas highlights CNS region-associated differences in expression programs of the glioma cells and in the immune cell composition of the tumor microenvironment.

IMMU-06. LANDSCAPE OF ADAPTIVE IMMUNITY OF CHILDHOOD BRAIN CANCERS

Itay Raphael[1], Maria Chikina[1], Alberto Broniscer[2,3], Ian Pollack[2,3], Dhivyaa Rajasundaram[1], Gary Kohanbash[1]; [1]University of Pittsburgh, Pittsburgh, Pennsylvania, USA. [2]University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. [3]Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA

T lymphocytes have a unique ability to recognize a vast array of antigens prompted by an enormous T cell receptor (TCR) repertoire. Characterization of tumor-infiltrating T cells (TILs) is key to understand MHC-restricted anti-tumor immunity and for developing T cell-centered immunotherapies such as adoptive cell therapy and tumor vaccines. In the current work, we investigated RNA-Seq data from 997 pediatric brain tumor patients and performed a large-scale comprehensive examination of the immunogenomic and TCR landscape of TILs across the entire spectrum of pediatric brain tumors. We show that the relative ratio between T cell diversity (clonality) and T cell abundance within each sample, represented by the clonal expansion index (CEI), is a strong predictor of prognosis both within and between tumor types. Interestingly, we show that CEI was strongly associated with molecular subgroups of medulloblastoma but not with known tumorgenomic features of these subgroups. Investigation of TCR clones recognizing a common recurrent tumor-antigen across patients based on CDR3 homology and characteristics, reveals 9 TCR clusters which are tumor type restricted with defined prognoses and HLA dominance. Using computational immunogenomics and machine learning-based investigations of these clusters yielded novel putative HLA-restricted tumor antigens which could bind and activate the clusters' specific TCRs. Importantly, our framework grounded the foundations for developing a precision medicine approach of T cell-centered immunotherapies. These findings have major implications for understanding the interplay between T cell and tumor genomic, and for developing new immunotherapies for children with brain tumors.

IMMU-07. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL T_{REG} DEPLETION AND DOUBLE CHECKPOINT BLOCKADE IN CHILDREN WITH RELAPSED HIGH-GRADE GLIOMAS.

Matthias Eyrich[1], Jürgen Krauss[2], Maryam Ghaffari[1], Ignazio Caruana[1], Johannes Rachor[1], Camelia-Maria Monoranu[3], Brigitte Bison[4], Stefan Rückriegel[2], Matthias Wölfl[1], Elisabeth Miller[1], Paul-Gerhardt Schlegel[1], Christof Kramm[5]; [1]University Children's Hospital, Würzburg, Germany. [2]University Hospital for Neurosurgery, Würzburg, Germany. [3]Institute for Pathology, Würzburg, Germany. [4]University

Medical Center, Augsburg, Germany. [5]University Children's Hospital, Göttingen, Germany

Relapses of high-grade gliomas show an aggressive course and survival 6 months after (sub-)total re-resection was only 62% in former HIT-HGG trials. Immunotherapy by induction of tumor-specific T cells through active immunization might help to control glioma regrowth. In the HIT-HGG-Rez Immunovac trial (Eudra-CT 2013-000419-26) we investigate whether a therapeutic vaccine (autologous dendritic cells loaded with tumor lysate, DCV) combined with T_{reg}-depletion and double checkpoint-inhibition (CI, anti-PD-1/anti-CTLA4) is able to increase the number of patients alive 6 months after relapse. Here, we report interim results after 50% of the intended patients (n=25) have been recruited. 13 children and adolescents (mean age 12.7±4.0 y) with relapsed glioblastomas were screened for the trial so far. Three patients were screening failures, 10 patients received study treatment. Of these, 2 patients are currently vaccinated, so that 8 patients were evaluable for this interim analysis. 5 SAEs have been reported so far, none of them was limiting. 4 patients with gross total or subtotal resection at time of relapse had an overall survival (OS) of 13.2±4.0 months and a 6-month survival rate of 100%, which compares favourably to historical controls. 4 partially resected patients survived only 5.1±1.3 months and 6-months OS was 25%. T_{reg}-depletion lead to a reduction of CD4+CD127-CD25+ T-cells of 45%, the majority of patients exhibited a tumor-specific T-cell response. We conclude that DCV in combination with partial T_{reg}-depletion and CI is feasible, safe, and related with immunological responses. Double CI was not associated with unexpected toxicities. In (sub-)totally resected patients, immunotherapy seems to confer a survival advantage. For the completion of the trial we aim to include more patients with (sub-)totally resectable tumors to gain more insight into the nature and duration of the induced immune response. This trial is supported by Bristol Myers-Squibb (CA209-7JA).

IMMU-08. NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE CNS MALIGNANCIES: EFFICACY, SAFETY, BIOMARKER, AND PHARMACOKINETIC RESULTS FROM CHECKMATE 908

Ira J. Dunkel[1], Kenneth Cohen[2], Nicholas K. Foreman[3], Darren Hargrave[4], Alvaro Lassaletta[5], Nicolas André[6], Jordan R. Hansford[7], Tim Hassall[8], Matthias Eyrich[9], Sridharan Gururangan[10], Ute Bartels[11], Amar Gajjar[12], Lisa Howell[13], Deepti Warad[14], Misena Pacius[15], Rachel Tam[14], Yu Wang[14], Li Zhu[14], François Doz[16]; [1]Memorial Sloan Kettering Cancer Center, New York, NY, USA. [2]The Johns Hopkins Hospital, Baltimore, MD, USA. [3]Children's Hospital Colorado, Aurora, CO, USA. [4]Great Ormond Street Hospital for Children, London, United Kingdom. [5]Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [6]Hopital pour Enfants de la Timone, AP-HM and Centre de Recherche en Cancérologie de Marseille, Aix Marseille Université, Marseille, France. [7]The Royal Children's Hospital, Murdoch Children's Research Institute, Department of Pediatrics, University of Melbourne, Melbourne, VIC, Australia. [8]Queensland Children's Hospital, South Brisbane, QLD, Australia. [9]Universitätsklinikum Würzburg, Würzburg, Germany. [10]Preston A. Wells Center for Brain Tumor Therapy, Gainesville, FL, USA. [11]The Hospital For Sick Children, Toronto, ON, Canada. [12]St. Jude's Children's Research Hospital, Memphis, TN, USA. [13]Alder Hey Children's Hospital, Liverpool, United Kingdom. [14]Bristol Myers Squibb, Princeton, NJ, USA. [15]Syneos Health©, Morrisville, NC, USA. [16]Institut Curie and University of Paris, Paris, France

BACKGROUND: Limited data exist regarding checkpoint inhibitor efficacy for pediatric CNS malignancies. METHODS: CheckMate 908 is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab (NIVO) and NIVO + ipilimumab (IPI) in 5 cohorts of pediatric patients previously treated with standard-of-care (NCT03130959). Patients received NIVO-3mg/kg Q2W or NIVO-3mg/kg + IPI-1mg/kg Q3W (4 doses) followed by NIVO-3mg/kg Q2W. Primary endpoints included OS (newly diagnosed DIPG) and PFS (other CNS cohorts); secondary endpoints included other efficacy metrics/safety. Exploratory endpoints included pharmacokinetics/biomarker analyses. Comparisons between treatments/cohorts were not planned. RESULTS: At data cutoff (13-Jan-2021), 166 patients received NIVO (n=85) or NIVO+IPI (n=81) at median (m) ages of 10.0yrs (range, 1-21) and 11.0yrs (1-21), respectively. In newly diagnosed DIPG, mOS (80% CI) was 11.7mos (10.3-16.5) with NIVO (n=23) and 10.8mos (9.1-15.8) with NIVO+IPI (n=22). In recurrent/progressive HGG, mPFS (80% CI) was 1.7mos (1.4-2.7) with NIVO (n=16) and 1.3mos (1.2-1.5) with NIVO+IPI (n=15). In relapsed/resistant medulloblastoma, mPFS (80% CI) was 1.4mos (1.2-1.4) with NIVO (n=15) and 2.8mos (1.5-4.5) with NIVO+IPI (n=15). In relapsed/resistant ependymoma, mPFS (80% CI) was 1.4mos (1.4-2.6) with NIVO (n=12) and 4.6mos (1.4-5.4) with NIVO+IPI (n=10). In other recurrent/progressive CNS tumors, mPFS (95% CI) was 1.2mos (1.1-1.3) with NIVO (n=19) and 1.6mos (1.3-3.5) with NIVO+IPI (n=19). Median treatment duration was 2.1mos (range, 0-41.7+ [NIVO]/0-29.6+ [NIVO+IPI]). Grade 3/4 treatment-related AEs occurred in 14.1% (NIVO) and 27.2% (NIVO+IPI) of